Adam Hedaya, MD
Interventional Pain Medicine · Mayfield Heights, OHNPI 1528171113
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 93 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $868 and has fallen 62.2% since, to $328 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in OH, where the typical reported total is $5,193.
Across 93 payments — averaging $31.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$641
- AbbVie$443
- Nevro Corp.$313
- Globus Medical$215
- Avanos Medical$214
- Nalu Medical, Inc.$179
- plus $903 from 22 others
What the payments were for
- Food & beverage$2,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 7 | $641 |
| AbbVie | 25 | $443 |
| Nevro Corp. | 6 | $313 |
| Globus Medical | 4 | $215 |
| Avanos Medical | 3 | $214 |
| Nalu Medical, Inc. | 4 | $179 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $169 |
| Boston Scientific | 7 | $136 |
| Biodelivery Sciences International, Inc. | 4 | $63 |
| Pfizer | 3 | $59 |
| Medtronic(2 entities) | 3 | $53 |
| Abbott | 2 | $50 |
| Stimwave Technologies Incorporated | 2 | $43 |
| Merz North America, Inc. | 3 | $38 |
| Vertex | 2 | $35 |
| Lilly USA, LLC | 2 | $30 |
| Pacira Therapeutics, Inc. | 1 | $30 |
| Novartis | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| MDD US Operations, LLC | 1 | $19 |
| Medline Industries LP | 1 | $17 |
| Curonix LLC | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Arteriocyte Medical Systems, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$434
- iFuse Implant$391
- GENERATOR$131
- NURTEC ODT$125
- Nalu Neurostimulation System$125
How this compares
$2,907 in reported general payments places this provider in the 30th percentile of 67 interventional pain medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 124 | $72,213 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $11,422 |
| Duloxetine Hcl | 228 | $8,313 |
| Pregabalin | 216 | $6,286 |
| Gabapentin | 302 | $3,751 |
| Tramadol Hcl | 307 | $3,559 |
| Lidocaine | 23 | $1,477 |
| Cyclobenzaprine Hcl | 85 | $1,227 |
| Tizanidine Hcl | 103 | $1,066 |
| Baclofen | 91 | $885 |
| Diclofenac Sodium | 39 | $848 |
| Celecoxib | 45 | $701 |
| Methocarbamol | 26 | $640 |
| Nortriptyline Hcl | 61 | $543 |
| Mirtazapine | 24 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $20 | $72,213124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 67 interventional pain medicine providers in Ohio.
Other interventional pain medicine in Mayfield Heights
- Gladstone McDowellColumbus$660K
- Humam AkbikFairfield$116K
- Sara NashiCincinnati$116K
- Jaudat MahmoodKent$97K
- Omar AliSpringfield$67K
- Dustin ReynoldsWesterville$61K
- James OttingToledo$47K
- Mark MalinowskiChillicothe$39K
- David WalegaColumbus$37K
- Ronald LinehanLancaster$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.